Ramon Bosser, CEO, Origo BioPharma
I would say that overall our experience with Eurofins Advinus has been very positive at all times. From the perspective of a small biotech like Origo, Eurofins Advinus fulfils all our requirements: flexibility, adherence to pre agreed timelines, adequate quality for the stage of development and no cost deviations! Our experience with them has been mostly on the IND packages including API and regulatory Toxicology. The approach the team of chemists has always been very proactive, looking for solutions, and keeping in mind the balance of quality vs time which is critical at early stages in development.
I would like also like to highlight that, the teams at Eurofins Advinus made a very significant effort to minimize the impact in timelines during the very difficult times of the COVID pandemics, we value this effort very much and are extremely grateful.